SCHEMBL14724516

SCHEMBL14724516

CCOC(=O)C(NC(=O)c1ccc(-c2ccccc2)cc1)C(=O)OCC

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.58
NPC1 O15118 4/20 0.58
CYP26A1 O43174 2/20 0.58
HPGDS O60760 1/20 0.54
CYP1A2 P05177 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP3A4 P08684 1/20 0.50
GAA P10253 2/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
CTDSP1 Q9GZU7 1/20 0.49
UTS2R Q9UKP6 1/20 0.48
HDAC3 O15379 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
NCOR2 Q9Y618 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14786692 0.93 CYP26A1 (0.55) RAB9ANPC1CYP26A1HPGDSCYP1A2
SCHEMBL5784044 0.91 SMN1; SMN2 (0.55) RAB9ANPC1CYP26A1ALDH1A1GAA
SCHEMBL9459929 0.84 SMN1; SMN2 (0.52) RAB9ANPC1CYP26A1ALDH1A1GAA
SCHEMBL5782189 0.84 KMT2A (0.54) RAB9ANPC1L3MBTL1ALDH1A1GAA
SCHEMBL2486914 0.83 SMN1; SMN2 (0.51) RAB9ANPC1CYP26A1ALDH1A1GAA
SCHEMBL28569685 0.83 CA12 (0.55) RAB9ANPC1CYP26A1ALDH1A1GAA
SCHEMBL17010276 0.83 ESR1 (0.56) CYP1A2ALDH1A1CYP3A4SMN1; SMN2
SCHEMBL14786715 0.81 TAS1R3 (0.43) RAB9ANPC1CYP26A1GAASMN1; SMN2
SCHEMBL655688 0.81 ALDH1A1 (0.56) NPC1ALDH1A1GAASMN1; SMN2HDAC3
SCHEMBL4652134 0.81 HTT (0.61) RAB9AL3MBTL1ALDH1A1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
EP-2562155-A1 NOVEL HYDROXAMIC ACID DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 RAB9A 2523/4885NPC1 3272/4885CYP26A1 2505/4885
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 RAB9A 2523/4885NPC1 3272/4885CYP26A1 2505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.